Shin Hatou, M.D., Ph.D., CEO
Tokyo, Japan

Virtual Presentation
Cellusion is a regenerative medicine startup founded by three professors at Keio University School of Medicine, Department of Ophthalmology in Japan. Cellusion has several unique technologies including a highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. The company’s lead program, CLS001 targeting Bullous Keratopathy, will start a first-in-human clinical study at Keio University Hospital soon. The company also has plans for several additional pipelines focusing on ophthalmologic diseases as well as other areas.

By using this website you agree to accept our Privacy Policy and Terms & Conditions